Achieve life sciences announces fda grants breakthrough therapy designation to cytisinicline for the treatment of e-cigarette or vaping nicotine dependence

Designation is based on results from the phase 2 orca-v1 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes compared with placebo designation is based on results from the phase 2 orca-v1 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes compared with placebo
ACHV Ratings Summary
ACHV Quant Ranking